B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL [Phase 1]
Phase 1 clinical trial update on cord blood-derived IL-10/IL-15 CD19-CAR NK cells for refractory/relapsed B-cell non-Hodgkin lymphoma, curre…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical trial of an in vivo CAR-T therapy for relapsed/refractory hematologic cancers is currently recruiting. The study targets …
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL [Phase 1]
This ClinicalTrials.gov entry reports a Phase 1 study of BAFFR-targeting CAR T cells for relapsed or refractory B-cell non-Hodgkin lymphoma,…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. [Phase 1]
Phase 1 clinical trial evaluating B019 Injection in relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiti…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A prospective Phase 1/2 clinical trial assessing a CD3-CD20 bispecific antibody–based therapy combined with CD19-CAR T cells for relapsed or…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms [Phase 1]
Phase 1 study of CT1195E in relapsed/refractory B-cell neoplasms is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) [Phase 1]
Phase 1 clinical trial update for CT1190B in relapsed/refractory B-cell non-Hodgkin lymphoma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy [Phase 2]
Phase 2 clinical trial evaluating anakinra to prevent or treat severe side effects in patients receiving CAR-T cell therapy; status is activ…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating radiation therapy before CAR T cell therapy for patients with B-cell non-Hod…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies [Phase 2]
This update reports a Phase 2 trial of loncastuximab tesirine for relapsed or refractory B-cell malignancies that is currently recruiting, i…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study [Phase 2]
Phase 2 clinical trial evaluating geriatric assessment-guided interventions to accelerate functional recovery after CAR-T therapy in patient…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma
Exploratory study evaluating Zebutinib as maintenance therapy after CAR-T treatment in patients with B-cell non-Hodgkin lymphoma; recruitmen…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 [Phase 1]
A Phase 1 clinical trial update describing CD19-targeted CAR T-cell immunotherapy for high-risk or relapsed CD19+ acute lymphoblastic leukem…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating decitabine-primed tandem CD19/CD20 CAR T cells in relapsed and refractory B-cell non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma [Phase 1]
A Phase 1 study of U01 (ssCART-19) for B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]
Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A status update on UCART20x22 in B-cell Non-Hodgkin Lymphoma showing Phase 1/Phase 2 trials currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) [EARLY_Phase 1]
This is an early Phase 1 dose-escalation trial evaluating a combined CD19/CD22/BCMA CAR-T therapy for relapsed or refractory B-cell non-Hodg…
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating JS203 combination regimens for B-cell non-Hodgkin's lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating a CD19/CD20 dual-targeted cellular therapy in relapsed/refractory B-cell non-Hodgkin lymphoma.
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
An update on an ongoing Phase 1/2 clinical trial evaluating Estrella Biopharma's EB103 T-cell therapy in adults with relapsed/refractory B-c…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1]
Phase 1 study evaluating ABO2203, an mRNA-encoded CD19/CD3 T cell engager, in patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical study evaluating CT1194C in relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruiting.